Catheter Precision Reports Significant Progress for LockeT
FORT MILL, S.C. — Catheter Precision, Inc. (VTAK - NYSE/American), a pioneering medical device company dedicated to providing innovative solutions for the cardiac electrophysiology sector, has announced that sales of its LockeT product are on course to achieve record highs in the second quarter of 2025. The company reports that sales figures have already surpassed those of the same quarter last year by an impressive 200%.
Growth in Hospital Adoption
Several hospitals in the U.S. are poised to place purchase orders exceeding $100,000 each for the LockeT device by the end of 2025. This remarkable progress includes partnerships with recognized institutions, contributing to the rise in product adoption. These hospitals are expected to play a crucial role in driving LockeT's market penetration.
Among the key hospitals engaging with Catheter Precision are Montefiore, Eisenhower Health, and Overland Park Regional Medical Center, all of which have shown substantial interest in integrating LockeT into their procedural offerings.
Strategic Moves in Europe
Following the granting of the CE Mark for LockeT, which allows sales in Europe, Catheter Precision has made strides in establishing a robust distribution network. The company has secured a distributor in Italy and is in the process of finalizing agreements with additional distributors in Spain, Portugal, and the UK, enhancing its European market reach.
CEO Insights on Future Plans
CEO David Jenkins expressed enthusiastic sentiments regarding the growth prospects, stating, “We are excited about the upcoming activities, our strong sales pipeline, and the increased product usage by our current customers, all contributing to heightened revenue from LockeT. A notable live demonstration is scheduled for June 16, where a key opinion leader will showcase LockeT during an Italian symposium. This event is expected to enhance the product's visibility and stimulate interest in the new market.”
Enhancing Product Awareness
Catheter Precision is actively engaging in strategies aimed at improving product awareness and expanding its footprint in Europe. With a commitment to collaborating with healthcare professionals, the company continues to advance its product offerings to meet market needs effectively.
About the LockeT Device
The LockeT is a specialized suture retention device designed to facilitate wound closure following percutaneous venous punctures. Classified as a Class 1 medical device, LockeT is registered with the FDA and is CE Mark approved, underscoring its safety and efficacy in clinical use.
About Catheter Precision
Catheter Precision stands out as an innovative U.S.-based medical device firm dedicated to improving treatment for cardiac arrhythmias. The company emphasizes developing cutting-edge technology for electrophysiology procedures through continuous collaboration with physicians, ensuring that its products evolve alongside clinical practices.
Frequently Asked Questions
What is the LockeT device?
The LockeT is a suture retention device designed to assist in wound closure after percutaneous venous punctures, helping improve patient outcomes.
How has sales of LockeT progressed?
Sales of LockeT for the second quarter of 2025 are projected to be the highest ever, showing an increase of 200% compared to the previous year.
Which hospitals are involved in purchasing LockeT?
Hospitals such as Montefiore, Eisenhower Health, and Overland Park Regional Medical Center are expected to place significant purchase orders for LockeT.
What are Catheter Precision's plans for the European market?
Catheter Precision has secured distribution in Italy and is looking to expand its presence in Spain, Portugal, and the UK, with plans to engage distributors in other EU countries as well.
Who leads Catheter Precision?
David Jenkins is the CEO of Catheter Precision, steering the company's innovative approach in the medical device sector.
